Clinical Trial Search

Primary: Number of Patients With no Disease Activity at Week 16 in the Study Eye — 89 Participants

Primary: Caliber of Choroidal New Vessel (CNV) — 43.53 micrometer

Primary: Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS)…

Primary: Change From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye to Month 2 — 9.5; -0.4 letters — p=<0.001

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Month 3 — .3; 6.8; 7.6 Letters

Primary: The Mean Percentage Change of the Area of the Patient's Neovascularization as Measured in Pixels by Optomap FA (Fluorescein Angiography) — -83.8; 52.6; 11.3; 55.4…

Primary: Percentage of Patients With Ocular Adverse Events (AEs) in the Study Eye — 48.5; 38.9 Percentage of Participants

Primary: Number of Participants With Ocular Adverse Events — 418; 56; 96; 59 participants

Primary: Mean Change From Baseline in BCVA Letter Score at Week 36, in Treatment-Naive Participants — 7.61; 9.18; 6.02; 6.10 BCVA Letters — p=0.5244

Primary: Percentage Change in Choroidal Neovascularization (CNV) Lesion Area Measured by Optical Coherence Tomography-Angiograph (OCT-A) From Baseline to Week 12 — -79.29 %…

Primary: Visual Acuity: Percentage of Patients Losing 3 or More Lines(15 Letters) of Visual Acuity From Baseline. — 80; 90 percent of participants

Primary: Average Change From Baseline to Month 1 Through Month 3 on Visual Acuity of the Study Eye — 55.4; 55.8; 54.7; 66.0 Letters

Primary: Number of Patients Treated and Re-treated Based on Presence/Absence of Active Leakage — 3; 0; 61; 121 Patients — p=<0.0001

Primary: Change From Baseline at Week 48 in Best-Corrected Visual Acuity in Study Eye — 9.9; 10.9 Letters Read — p=0.006

Primary: Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12 — 53.7; 54.6; 54.8; 59.0 Letters

Primary: Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline to Week 24 - Last Observation Carried…

Primary: Incidence of Adverse Events — 3; 4 Participants

Primary: Primary Outcome: Change in Visual Acuity (LogMAR Letters) From Baseline to Detection of Choroidal Neovascularization — -7.4; -12.6 LogMAR letters (ETDRS)

Primary: Commonly Reported and Notable Adverse Events — 1; 2; 2; 3 participants

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 — 10.1; 9.2; 8.2; 8.6 Letters

Primary: Mean Change From Baseline in Best-corrected Visual Acuity of the Study Eye at Month 12 — 4.9; 3.8; 8.3 letters

Primary: Change in Visual Acuity (Sildenafil Group) — 0.00; -0.03 logMAR

Primary: Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores From Baseline to Week 52 - Last…

Primary: Mean Change in Visual Acuity (Logarithm of the Minimum Angle of Resolution [LogMAR]) Score From Baseline for IGIV-C, 10% Compared to Placebo at Week 12 or at Last LogMAR…

Primary: Number of Subjects With Positive LUCENTIS® Retreatment Status at Day 84 — 25; 25 Participants

Primary: Incidence and Severity of Ocular Adverse Event — 0 participants

Primary: Change From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 3 — 53.7; 54.2; 52.6; 63.1 ETDRS letters — p=<0.001

Primary: Heart Rate — 68.7 Beats per Minutes

Primary: Improvement in VA ETDRS >/= 15 Letters — 1 participants

Primary: Vision — 0.16 logMAR